US needs suspension option for risk-benefit decision making
This article was originally published in Scrip
Executive Summary
Abbott Laboratories' "voluntary" decision to withdraw the anti-obesity drug Meridia in the US raises more questions as to how the regulatory bodies in the US and the EU deal with products whose benefit-risk profiles are judged wanting.